{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:26:53Z","timestamp":1788449213120,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijgc.2025.102800","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T09:12:25Z","timestamp":1763111545000},"page":"102800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pelvic radiotherapy combined with immunotherapy and chemotherapy for stage IVB cervical cancer: a retrospective study"],"prefix":"10.1016","volume":"36","author":[{"given":"Jian","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingting","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3450-4787","authenticated-orcid":false,"given":"Chaoxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijgc.2025.102800_bib1","first-page":"221","article-title":"[Cancer incidence and mortality in China, 2022]","volume":"46","author":"Zheng","year":"2024","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102800_bib2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ygyno.2019.10.033","article-title":"Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: a novel treatment strategy","volume":"156","author":"Perkins","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.102800_bib3","article-title":"Definitive vs palliative pelvic radiation for patients with newly diagnosed stage IVB cervical cancer treated with bevacizumab - an exploratory study","volume":"40","author":"Wiley","year":"2022","journal-title":"Gynecol Oncol Rep"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102800_bib4","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1016\/j.prro.2018.05.010","article-title":"Definitive local therapy is associated with improved overall survival in metastatic cervical cancer","volume":"8","author":"Venigalla","year":"2018","journal-title":"Pract Radiat Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102800_bib5","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/ijgo.70077","article-title":"The association between additional radiotherapy after systemic chemotherapy and the prognosis of stage FIGO 2018 IVB cervical cancer","volume":"170","author":"Miyoshi","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102800_bib6","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/ijgc-2020-001200","article-title":"Effect of addition of bevacizumab to chemoradiotherapy in newly diagnosed stage IVB cervical cancer: a single institution experience in Korea","volume":"30","author":"Youn","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"36","key":"10.1016\/j.ijgc.2025.102800_bib7","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.23.00914","article-title":"First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102800_bib8","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40264-018-0774-8","article-title":"Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer","volume":"42","author":"Baraibar","year":"2019","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102800_bib9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"10103","key":"10.1016\/j.ijgc.2025.102800_bib10","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"issue":"10421","key":"10.1016\/j.ijgc.2025.102800_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"issue":"10463","key":"10.1016\/j.ijgc.2025.102800_bib12","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"Lancet"},{"issue":"10434","key":"10.1016\/j.ijgc.2025.102800_bib13","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial","volume":"403","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102800_bib14","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/ijgc-2019-001135","article-title":"CALLA: efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study","volume":"30","author":"Mayadev","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102800_bib15","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s12094-017-1808-x","article-title":"Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in \u201creal world\u201d patients","volume":"20","author":"Godoy-Ortiz","year":"2018","journal-title":"Clin Transl Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2501922X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2501922X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T21:20:20Z","timestamp":1780003220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2501922X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1048891X2501922X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102800","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pelvic radiotherapy combined with immunotherapy and chemotherapy for stage IVB cervical cancer: a retrospective study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102800"}}